Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome

Thyroid

Volumn 24, Issue 6, 2014, Pages 1062-1066

  Barroso Sousa, Romualdo ^a   Lerario, Antonio Marcondes ^a   Evangelista, Joao ^a   Papadia, Carla ^a   Lourenço, Delmar M ^a   Lin, Chin Shien ^a   Kulcsar, Marco Antonio ^a   Fragoso, Maria Candida ^a   Hoff, Ana O ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CORTICOTROPIN; METYRAPONE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADULT; ADVANCED CANCER; ARTICLE; ASTHENIA; CASE REPORT; CUSHING DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; ECTOPIC CORTICOTROPIN PRODUCTION; EYE PAIN; FOOT PAIN; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERCORTISOLISM; MALE; METASTASIS; MOLECULARLY TARGETED THERAPY; OFF LABEL DRUG USE; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; TREATMENT OUTCOME; ACTH SYNDROME, ECTOPIC; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HYPOPHYSIS ADRENAL SYSTEM; MIDDLE AGED; THYROID TUMOR;

ACTH SYNDROME, ECTOPIC; HUMANS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PITUITARY-ADRENAL SYSTEM; THYROID NEOPLASMS;

EID: 84902187709     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0571     Document Type: Article

References (19)

1. 1. Almeida MQ, Hoff AO 2012 Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. Curr Opin Oncol 24:229-234.
2. Wells SA Jr, Santoro M 2009 Targeting the RET pathway in thyroid cancer. Clin Cancer Res 15:7119-7123.
3. Moura MM, Cavaco BM, Pinto AE, Leite V 2011 High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 96:E863-E868.
4. Boichard A, Croux L, Al GA, Broutin S, Dupuy C, Leboulleux S, Schlumberger M, Bidart JM, Lacroix L 2012 Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab 97:E2031-E2035.
5. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ 2012 Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 30:134-141.
6. Schoffski P, Elisei R, Muller S, et al. 2012 An international, double-blind, randomized, placebo-controlled Phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol 30: Suppl:5508. abstract.
7. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH 2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323-2330.
8. Orth DN 1995 Cushing's syndrome. N Engl J Med 332:791-803.
9. Boscaro M, Arnaldi G 2009 Approach to the patient with possible Cushing's syndrome. J Clin Endocrinol Metab 94:3121-3131.
10. Barbosa SL, Rodien P, Leboulleux S, Niccoli-Sire P, Kraimps JL, Caron P, Archambeaud-Mouveroux F, Conte-Devolx B, Rohmer V 2005 Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: A retrospective analysis and review of the literature. Thyroid 15:618-623. (Pubitemid 40993738)
11. Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, Melmed S 2011 EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 121:4712-4721.
12. Carbajal L, Biswas A, Niswander LM, Prizant H, Hammes SR 2011 GPCR/EGFR cross talk is conserved in gonadal and adrenal steroidogenesis but is uniquely regulated by matrix metalloproteinases 2 and 9 in the ovary. Mol Endocrinol 25:1055-1065.
13. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM 2006 VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560-H576.
14. Patyna S, Arrigoni C, Terron A, Kim TW, Heward JK, Vonderfecht SL, Denlinger R, Turnquist SE, Evering W 2008 Nonclinical safety evaluation of sunitinib: A potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors. Toxicol Pathol 36:905-916.
15. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R, Pazdur R 2007 Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12: 107-113. (Pubitemid 46143508)
16. Lodish MB 2013 Kinase inhibitors: Adverse effects related to the endocrine system. J Clin Endocrinol Metab 98:1333-1342.
17. Makita N, Iiri T 2013 Tyrosine kinase inhibitor-induced thyroid disorders: A review and hypothesis. Thyroid 23:151-159.
18. Baudry C, Paepegaey AC, Groussin L 2013 Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma. N Engl J Med 369:584-586.
19. Fox E, Widemann BC, Chuk MK, Marcus L, Aikin A, Whitcomb PO, Merino MJ, Lodish M, Dombi E, Steinberg SM, Wells SA, Balis FM 2013 Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res 19:4239-4248.